Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
LEXINGTON, Massachusetts, August 3 /PRNewswire-FirstCall/ -- Shire plc
(LSE: SHP, NASDAQ: SHPGY ), the global specialty biopharmaceutical company,
today reported positive results from the first of three
Phase III studies of
velaglucerase alfa, its enzyme replacement therapy in development fo...
Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications
aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases
SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application on proprietary, naturally occurring, resected hu...
Families of Spinal Muscular Atrophy Announces Latest Developments on Three SMA Drug Discovery Programs
LIBERTYVILLE, Ill., June 18 /PRNewswire-USNewswire/ -- Families of Spinal Muscular Atrophy has just released details of the latest developments for the Families of SMA funded therapeutic pipeline.
Families of SMA is currently funding three
distinct drug discovery programs: 1) Quinazolines to ...
Merz Pharmaceuticals Announce Three Studies of NT-201 - (Botulinum neurotoxin type A Free From Complexing Proteins)
-Second Data Set Presented at MDS-
PARIS, June 9 /PRNewswire/ -- Results from three
placebo controlled studies conducted to assess NT-201 in upper limb post-stroke spasticity, pre-treated cervical dystonia, and treatment-naive cervical dystonia patients represent the second data set presented...
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
- Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R) -
NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. presented results of a new study, "Effects of 1, 2, or 3 Prandial Injections of ...
Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
- 71% Objective Tumor Response in Combination with Docetaxel in Advanced Breast Cancer -
- 65% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Lung Cancer -
- 64% Objective Tumor Response in Combination with Carboplatin/Paclitaxel in Advanced Breast Cance...
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
- Significant peak urine flow (Qmax) improvements within 2-6 hours of the first dose, according to published data -
CORONA, Calif., May 8 /PRNewswire-FirstCall/ -- RAPAFLO (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and symptoms of BPH, produ...
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
SEATTLE, April 28 /PRNewswire/ -- Results from two prospective, double-blind placebo controlled multi-center studies in patients with cervical dystonia and blepharospasm, and pooled European efficacy and safety data in patients with focal dystonia and upper limb spasticity will be presented at th...
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Company to Submit a Supplemental New Drug Application to Expand the NUVIGIL(R) Label
FRAZER, Pa., April 6 /PRNewswire-FirstCall/ -- Cephalon, Inc . (Nasdaq: CEPH ) today announced positive results from a phase three
clinical trial of NUVIGIL(R) (armodafinil) Tablets [...
Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
In SPIRIT II Trial, XIENCE V Drug Eluting Stent Demonstrates Clinically Meaningful Reductions Compared to TAXUS in Key Safety Endpoints, Including an 88 Percent Reduction in the Risk of Cardiac Death at Three
ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- Long-term data presen...
Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
Company Expects to Deliver Multiple Clinical Milestones throughout the Year; Amigal to Initiate Phase 3 Global Development in Second Quarter; Continued Strong Financial Position
CRANBURY, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ) today announced positive pr...
Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
Long-term benefits of preventing heart attacks highlighted in new study presented at global health outcomes meeting
ATHENS, Greece, Nov. 9 /PRNewswire-FirstCall/ -- Despite substantial
progress in the diagnosis and treatment of heart attack patients,
prevention of recurrent heart ...
First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
Multi-Disciplinary Oversight Panel Includes American Brachytherapy Society,
American Society of Breast Surgeons and American College of Radiation Oncology
SUNNYVALE, Calif., June 24 /PRNewswire/ -- Xoft, Inc. today announced
the launch and of the EXIBT Study (El...
Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO'08
SAN DIEGO, June 18 /PRNewswire/ -- Kansas researchers and companies
excel in the human health biosciences, and $3.7 million in new Kansas
Bioscience Authority (KBA) investments in that sector will support
cutting-edge innovations for the treatment of cancer, HIV, and
osteoporosis, as well as i...
Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease
Company to Continue Focus on Pipeline and Haptoglobin Diagnostic Assay
MONTVALE, N.J., June 6 /PRNewswire-FirstCall/ -- Synvista Therapeutics,
Inc. (Amex: SYI ) today announced data from three
Phase 2 trials (Trials
201a, 201 and 203) of SYI-2074 in Type 2 diabetic patients. Trial 201a
Ipsogen Announces Three Studies at the American Society of Clinical Oncology (ASCO) Meeting Extending the Utility of the Genomic Grade Index for Predicting Response to Chemotherapy in Breast Cancer
MARSEILLE, France, May 19 /PRNewswire/ -- IPSOGEN SA (Marseille and New
Haven), a cancer profiler that develops and markets molecular diagnostic
assays for blood & breast cancers, announced today that researchers from
the University of Texas MD Anderson Cancer Center (MDACC, Houston, TX) will
FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment
- Phase II study extension shows 68-73% of patients with multiple sclerosis
remained relapse-free after three
years of treatment with oral FTY720
- New data demonstrate 89% of patients free from active brain lesions - the injury caused by MS - three
years after starting treatment
- MS, ...
Family of Three Americans Become Pain Free and Improve Their Quality of Life With Stem Cell Treatment in Mexico
MONTERREY, Mexico, March 20 /PRNewswire/ -- Optimum Health Regeneration
Center announced the successful treatment of an American family treated for
pain management and impaired mobility. This New Mexico family, ranging in
age from 52 to 78, all recorded significant improvements in reduced pain...
Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
- HspE7 Well Tolerated; Fourth Cohort to be Dosed Shortly -
SAN DIEGO, March 3 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals
Corporation (TSX: NVN) today announced the completion of the safety and
tolerability assessment of its third cohort of patients in a Phase 1
clinical trial o...
TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
New AcuCare Programs Automate the Interface between Health Assessments for Patients and the Generation of Customized Care Treatment Plans
AUBURN, Calif., Jan. 22 /PRNewswire/ -- TCS Healthcare Technologies, an
industry leader in the development of medical management software
Despite Serious Health Risks, One in Three Adults with Heart Disease Does Not Believe They Need a Flu Shot This Year
DALLAS, Nov. 1 /PRNewswire-USNewswire/ -- Death resulting from
influenza, often referred to as "the flu," is more common among individuals
with heart disease than among patients with any other chronic medical
condition. However, according to a new nationwide survey of heart disease
Data from Three Clinical Trials for Perforomist(TM) Inhalation Solution to be Presented at CHEST 2007 on October 24, 2007
- Presentations on long-term safety and cardiovascular safety of nebulized
formoterol fumarate and safety/ efficacy of concomitant use with tiotropium for treatment of COPD -
NAPA, Calif., Oct. 16 /PRNewswire/ -- Dey, L.P., a subsidiary of Mylan
Inc. (NYSE: MYL ), announ...
Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week
Variety of new applications spans paleogenomics, paired-end mapping, and gene expression analysis
BRANFORD, Conn., Oct. 2 /PRNewswire/ -- 454 Life Sciences, a Roche
company, is the subject of three
ground-breaking studies published last
week in Science, all of which empl...
ViroPharma to Present at Three Upcoming Healthcare Conferences
EXTON, Pa., Aug. 30 /PRNewswire-FirstCall/ -- ViroPharma Incorporated
(Nasdaq: VPHM ) today announced that Vincent Milano, vice-president, chief
operating officer and chief financial officer of ViroPharma, will present
at the Thomas Weisel Partners 2007 Healthcare Conference at 8:00 A.M. ET o...
EntreMed Presents Mechanism Data for Its Three Lead Oncology
Multiple Mechanisms for Panzem NCD, MKC-1, and ENMD-1198
Highlighted at Oncology Drug Discovery Conference
ROCKVILLE, Md., March 26, 2007 /PRNewswire-FirstCall/ --
EntreMed, Inc., a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases,...
Data supporting three Antisoma programmes presented at AACR
LONDON, and LOS ANGELES, 16 April 2007- Antisoma announces that
preclinical data supporting three
of its drugs are presented this
week at the Annual Meeting of the American Association of Cancer
AS1404-Avastin-paclitaxel triple combination highly effective
Antisoma's scientists ...
Spectrum Pharmaceuticals Announces Data From Three Oncology
Programs Presented at the American Association of Cancer Research
1 EOquin Instillation Immediately Following Transurethral Resection
is Well Tolerated in Phase 2b Bladder Cancer Study
IRVINE, Calif., April 19, 2007 /PRNewswire-FirstCall/ --
Spectrum Pharmaceuticals, Inc., today announced results of a Phase
2b study of EOquin, in non-invasive bladder cancer and ...
Isotechnika Announces Interim Three Month Data from Phase 2b Kidney
EDMONTON, May 07, 2007 /PRNewswire-FirstCall/ - Isotechnika Inc.
today announced the audited three
month results, reviewed by the
Data Monitoring Committee, of the first third of the patients
treated in its Phase 2b de novo kidney transplant trial for the
Company's lead immunosuppressive drug, ISA...
Separate Sets of Research Show Treatment Improved Quality of Life
in as Early as Three Weeks; Patient Adherence to Medication is
WASHINGTON, May 22, 2007 /PRNewswire/ -- Results from analyses
looking at factors contributing to successful treatment of
ulcerative colitis (UC), were presented at Digestive Disease Week
(DDW) this week. Both of these studies were funded by Procter &
Gamble (P&G) Pharmaceuticals, Inc. Fin...
ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds
for Solid Tumors Are to be Reported at ASCO
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 24, 2007 - ImmunoGen, Inc.
(Nasdaq: IMGN), a biopharmaceutical company that develops targeted
anticancer therapeutics using its Tumor-Activated Prodrug (TAP)
technology, today announced that clinical findings for three
different TAP compounds for the treatment...
Byetta Treatment for Three and a Half Years Associated with
Reductions in Cardiovascular Risk Factors in People with Type 2
- BYETTA also Showed Sustained Improvements in Blood Glucose
Control and Progressive Weight Loss -
CHICAGO, June 23, 2007 /PRNewswire-FirstCall/ -- Amylin
Pharmaceuticals, Inc. and Eli Lilly and Company today announced
results from a study that showed BYETTA(R) (exenatide) injection
Regular Yoga Practice Is Associated With Mindful Eating
...rld-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Our researchers, including three
Nobel laureates, bring a relentless pursuit and passion for health, knowledge and hope to their work and to the world. For more information, please vi...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...drug in 2009; clinical trials already initiated on three
drugs this year
Expand pipeline by moving a...perations of $4.8 million and $5.5 million for the three
and six months ended June 30, 2009, respectively, ...and a loss from operations of $5.2 million for the three
and six months ended June 30, 2008, respectively. ...
Radius' Investigational Bone Anabolic Agent, BA058, Increased Bone Mineral Density (BMD) at Key Fracture Sites in Phase 2 Clinical Trial in Postmenopausal Osteoporosis
...ient Phase 2 clinical trial was to assess safety and evaluate the effect of three
doses of BA058 on bone formation markers and on lumbar spine and femoral ne...inued throughout the study. Treatment was randomized to Forteo(R) or one of three
doses of BA058 (20, 40, or 80 micrograms), or matching placebo. The study's...
Labopharm files New Drug Submission with Health Canada for novel antidepressant
...e group administered Labopharm's trazodone. In addition, patients on Labopharm's trazodone demonstrated significant improvements versus placebo in all three
quality of sleep end points, with an improvement by the first week of therapy in "overall quality of sleep" and "awakening during the night". The inci...
Nektar Therapeutics Reports Second Quarter 2009 Financial Results
...ktar preclinical and clinical development programs.
Revenue for the three
month period ended June 30, 2009 was $13.0 million compared to revenue of $... information)
Months Ended Six Months Ended
June 30, ...
Study Shows Brain Fitness can Save Medicare Billions
...endent and Vital Elderly (ACTIVE) study. There were 2,802 healthy adults, aged 65 and older, enrolled in the study. The participants were divided into three
intervention groups and a no contact control group. The intervention groups received classroom training in reasoning or memory strategies or took part...
Scientists Discover Origin of Malaria
...d wild-born captive chimpanzees in Cameroon and Ivory Coast. In Cameroon researchers collected samples from chimpanzees during routine health exams in three
different wildlife sanctuaries. They were primarily wild-born animals brought to the sanctuaries after being confiscated by authorities or abandoned b...
Project Zero Delay Accelerates Drug's Path to Clinical Trial
...two days after U.S. Food and Drug Administration clearance of the experimental drug for a first-in-human cancer trial, a milestone that normally takes three
to six months. Investigators from The University of Texas M. D. Anderson Cancer Center and pharmaceutical company AstraZeneca have reported their work...
TWO NEW KLRI PEER-REVIEWED PUBLICATIONS: Hormone Therapy May Reduce Atherosclerosis in Women Close to Menopause; Growth Hormone May Increase Risk of Diabetes, Improve Lipid Profile in Men
... KLRI's Director and President.
The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial compared conjugated equine estrogen (CEE) with three
different CEE-progestin combinations and placebo in 875 healthy, postmenopausal women, aged 45 to 64. KLRI has found that other trial results used by ...